OCX | OncoCyte Corporation
Category: Biotechnology company
Industry: Biotechnology company Quick infos Headquarters: California, United States Trade prices Volume: Market Cap: 141.03M Prev closed: 4.06 Open: 4.14 High: 4.55 Low: 4.06 52 week low: 1.15 52 week high: 6.57 Dividends: No Dividends Next ER: May 11, 2022 After Market Closes
Company Profile Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the lung cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment.
Earnings History Date EPS / Forecast Revenue / Forecast March 10, 2022 -0.39 / -0.12293.59M / 3.52MBeat! November 9, 2021 -0.15 / -0.115984K / 1.75MBeat! August 10, 2021 -0.12 / -0.10062.03M / 1.57MBeat! May 17, 2021 -0.05 / -0.09871.12M / 838.02KMarch 16, 2021 -0.09 / -0.1075503K / 807.9Kview more
Historical Data Date Price Open High Low Vol Change ER May 6, 2022 1.150 1.170 1.170
1.140
613.41K -3.36% May 5, 2022 1.190 1.180 1.250
1.170
559.85K -1.65% May 4, 2022 1.210 1.160 1.220
1.160
411.71K 3.42% May 3, 2022 1.170 1.170 1.200
1.155
359.70K 0% May 2, 2022 1.170 1.160 1.180
1.140
512.73K 0.86% Apr 29, 2022 1.160 1.130 1.160
1.130
508.46K 2.65% Apr 28, 2022 1.130 1.130 1.140
1.120
401.57K 0% Apr 27, 2022 1.130 1.150 1.160
1.130
891.47K -1.74% Apr 26, 2022 1.150 1.150 1.169
1.140
838.34K 1.77% Apr 25, 2022 1.130 1.140 1.190
1.120
787.92K -1.74% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company Founded:2009 Employees:33 Parent Organization : BioTime News
Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants finance.yahoo.com May 25, 2022 5:12 pm
Oncocyte Reports First Quarter 2022 Financial Results finance.yahoo.com May 11, 2022 4:05 pm
Oncocyte to Announce First Quarter 2022 Financial Results finance.yahoo.com Apr 28, 2022 4:01 pm
A number of insiders bought OncoCyte Corporation (NASDAQ:OCX) stock last year, which is great news for shareholders finance.yahoo.com Apr 22, 2022 9:26 am
Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update finance.yahoo.com Mar 10, 2022 4:05 pm
Shareholders in OncoCyte (NASDAQ:OCX) have lost 78%, as stock drops 12% this past week finance.yahoo.com Feb 21, 2022 7:26 am
Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology finance.yahoo.com Jan 18, 2022 4:05 pm
Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution of DetermaRx in China finance.yahoo.com Dec 8, 2021 8:00 am
Will OncoCyte (OCX) Report Negative Earnings Next Week? What You Should Know finance.yahoo.com Nov 2, 2021 3:02 pm
Is the Options Market Predicting a Spike in OncoCyte (OCX) Stock? finance.yahoo.com Aug 18, 2021 8:49 am
Will OncoCyte (OCX) Report Negative Earnings Next Week? What You Should Know finance.yahoo.com Aug 3, 2021 3:00 pm
Here's What OncoCyte Corporation's (NASDAQ:OCX) Shareholder Ownership Structure Looks Like finance.yahoo.com Jul 8, 2021 5:34 am
EchelonDx and Oncocyte Announce Collaboration to Create Seamless Informatics Software to Scale Proprietary Clinical Test Offerings finance.yahoo.com Jun 15, 2021 8:03 am
Will OncoCyte (OCX) Report Negative Q1 Earnings? What You Should Know finance.yahoo.com May 19, 2021 3:00 pm
OncoCyte Corp. to Host Earnings Call finance.yahoo.com May 19, 2021 2:30 pm
Oncocyte Announces Pricing of $35 Million Public Offering of Common Stock finance.yahoo.com May 19, 2021 8:25 am OncoCyte EPS beats by $0.05, beats on revenue seekingalpha.com May 18, 2021 4:01 am
Oncocyte Presents Confirmatory Data for DetermaIO at the American Association for Cancer Research Annual Meeting 2022 finance.yahoo.com Apr 11, 2022 8:00 am
Oncocyte Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer finance.yahoo.com Jan 4, 2022 8:00 am
Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium 2021 finance.yahoo.com Dec 2, 2021 8:00 am This company doesn't provide a dividend.
Key Persons Talk about OncoCyte Corporation below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.